Minhua Chu· @chuminhua432 · X·· 2026-04-18Score60
Reading
PD-1 × VEGF bispecifics after ivonescimab
That MK-2010’s data are entirely from China is itself an industry signal: Merck is willing to refill post-PD-1 through this path.
Body
#AACR26
$MRK will present clinical data for MK-2010, a PD-1/VEGF bispecific antibody drug acquired from LaNova Medicines, via oral presentation on April 20. All data will be from clinical trials in China.
Abstract:
https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/CT057/782906/Abstract-CT057-Preliminary-results-from-the-first?searchresult=1
…
The first-in-human data from a
Heat 16 · 16 likes · 0 replies · 0 reposts
Source: Minhua Chu · x.com